相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
20.0%
招募中
2
40.0%
终止
1
20.0%
撤回
1
20.0%
暂无批准数据
- AstronauTx has appointed Dr. Michelle Mellion as Chief Medical Officer, bringing over 20 years of neurology and clinical development experience to advance the company's sleep architecture-targeting therapeutics. - The company is developing first-in-class therapies that target sleep architecture as a potential disease-modifying strategy for Alzheimer's disease and other neurological disorders. - AstronauTx's innovative approach uses EEG-based sleep architecture metrics and advanced data analytics to improve slow-wave sleep quality and potentially slow cognitive decline. - The appointments strengthen the company's clinical capabilities as it prepares to initiate clinical development of its pipeline following a $61 million Series A financing in October 2023.
- PepGen received a U.S. composition of matter patent for PGN-EDODM1, providing exclusivity until the second half of 2042 with potential extension following FDA approval. - The investigational therapy targets myotonic dystrophy type 1, a severe neuromuscular disease with no approved therapies addressing its underlying cause. - PGN-EDODM1 utilizes PepGen's proprietary Enhanced Delivery Oligonucleotide platform to restore normal RNA splicing function by liberating the MBNL1 protein. - The FDA has granted PGN-EDODM1 both Orphan Drug and Fast Track Designations for DM1 treatment.
- PepGen completed a $115 million public offering of 35.9 million shares at $3.20 per share to fund ongoing clinical development programs. - The biotechnology company will use proceeds to advance FREEDOM-DM1 and FREEDOM2-DM1 clinical trials targeting severe neuromuscular and neurological diseases. - PepGen's Enhanced Delivery Oligonucleotide platform leverages cell-penetrating peptides to improve therapeutic uptake and activity. - The funding supports the company's mission to transform treatment of serious diseases by targeting their root causes with next-generation oligonucleotide therapies.
- PepGen's PGN-EDODM1 demonstrated a mean splicing correction of 53.7% at 15 mg/kg dose in DM1 patients, representing the highest splicing correction ever reported in this patient population. - All six patients (100%) receiving the 15 mg/kg dose showed improved splicing correction, with the therapy demonstrating greater than dose-proportional increases across all tested doses. - The treatment was generally well-tolerated with no serious adverse events, while PepGen's stock surged 121.8% following the announcement of these breakthrough results.
• Phase I/II Deliver trial demonstrates sustained functional improvements in DMD patients treated with DYNE-251, showing mean absolute dystrophin expression of 8.72% above baseline at six months with the 20mg/kg dose. • The therapy, designed for patients amenable to exon 51 skipping, showed improvements across multiple functional endpoints including mobility assessments, positioning Dyne for potential accelerated FDA approval submission in early 2026. • If approved, DYNE-251 could generate significant market impact, with GlobalData projecting revenue growth from $5 million in 2025 to $129 million by 2030 in the competitive DMD treatment landscape.
- Initial results from FREEDOM-DM1 trial demonstrate significant splicing correction of 29.1% at 10 mg/kg dose in patients with Myotonic Dystrophy Type 1, showing potential therapeutic efficacy. - PepGen's EDO platform technology successfully delivers PGN-EDODM1 to the cellular nucleus, addressing the fundamental mechanism of DM1 disease progression. - Company advances clinical program with ongoing 15 mg/kg cohort in FREEDOM-DM1 trial and fully enrolled 10 mg/kg cohort in CONNECT1-EDO51 study, with results expected in late 2025.
• The FDA granted breakthrough therapy designation to STK-001 for Dravet syndrome, highlighting its potential to improve upon current treatments by restoring NaV1.1 protein levels. • Tolebrutinib received breakthrough therapy designation for non-relapsing secondary progressive multiple sclerosis based on phase 3 trial results showing delayed disability progression. • The FDA placed a clinical hold on PepGen’s PGN-EDO51 phase 2 study for Duchenne muscular dystrophy, pending further clarification from the agency.
- The FDA has placed a clinical hold on PepGen's Phase 2 CONNECT2-EDO51 trial for PGN-EDO51 in Duchenne muscular dystrophy (DMD) due to regulatory questions. - Sanofi's tolebrutinib, a BTK inhibitor, received breakthrough therapy designation from the FDA for non-relapsing secondary progressive multiple sclerosis (nrSPMS). - Edgewise Therapeutics' sevasemten met its primary endpoint in a Phase 2 trial for Becker muscular dystrophy, showing a significant decrease in creatine kinase.
- The FDA has approved Neurocrine's Crenessity as an adjunct therapy for classic congenital adrenal hyperplasia, offering patients a way to reduce steroid treatment burden. - Checkpoint Therapeutics received FDA approval for Unloxcyt to treat advanced cutaneous squamous cell carcinoma, targeting a $1 billion market opportunity. - Galderma's Nemluvio gains FDA approval for moderate-to-severe atopic dermatitis in patients 12 and older, with projected peak annual sales exceeding $2 billion.
• The myotonic dystrophy therapeutic landscape is experiencing a surge in R&D, with over 20 companies actively involved in developing 22+ novel therapies. • Key players like Avidity Biosciences, Dyne Therapeutics, and Vertex Pharmaceuticals are advancing promising drugs such as AOC 1001, DYNE-101, and VX-670 through clinical trials. • Regulatory designations, including Breakthrough Therapy and Fast Track, have been granted to several pipeline drugs, expediting their development for myotonic dystrophy. • Recent clinical trial initiations and data presentations highlight the progress in addressing unmet needs in myotonic dystrophy treatment, fostering hope for improved patient outcomes.
